Clinical trial of WHO multibacillary multidrug therapy versus rifampicin, moxifloxacin and clarithromycin on multibacillary leprosy patients from India
Phase 3
- Conditions
- eprosyInfections and Infestations
- Registration Number
- ISRCTN70846313
- Lead Sponsor
- The Leprosy Mission Trust India
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 280
Inclusion Criteria
1. Age 15 years and above
2. Multibacillary (MB) leprosy, defined as 5 or more skin lesions or extensive infiltration and/or diffuse skin involvement, classified as borderline tuberculoid, borderline lepromatous or polar lepromatous, as determined using the Ridley and Jopling classification system
3. Never treated before for leprosy
Exclusion Criteria
1. History of intolerance to one of the medications
2. Patients who are not able to come to the clinic every month during their treatment and during follow-up
3. Patients who do not give informed consent or are not capable of giving informed consent due to mental impairment
4. Immunocompromised patients diagnosed with HIV/AIDS and tuberculosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method